… drug for formulary uptake. … for formulary uptake of biosimilar low molecular weight heparin
by the use of the System of Objectified Judgment Analysis/Infomatrix system. Note: Weight …

… sequent-entry biologics (ie biosimilars), also strictly applicable to the regulation of biologics
… to enoxaparin within an institution’s formulary did not compromise patient safety after major …

… heparin) are losing market exclusivity worldwide, inviting the generic/biosimilar drug … (GAG)
of animal origin having weight-average molecular weight (M w ) of ~ 12,000 Da …

… The increasing availability of biosimilar LMWH formulations … and by its inclusion in hospital
formularies. In a survey of 224 … their highly complex molecular structure or biological origin. …

… biosimilar heparin derivatives force them to look for less costly raw materials than those used
in unfractionated heparin of porcine origin… regarding their organizations’ formularies, and in …

… approved in Europe, but biosimilar products may be considered … crude heparin to verify the
porcine origin of the crude heparin (… In: United States Pharmacopeia and National Formulary (…

… highly purified heparin lyase of bacterial origin., Heparin lyase … Recently, various patents for
low molecular weight heparin … , leading to generic or biosimilar products that capture market …

… biosimilars in the United States. For instance, the FDA approved nonoriginator low-molecular-weight
heparin … Authorization for nonlabeled uses of a biosimilar within a formulary system …

… heparin “biosimilars.” Based on experience with generic, … for the decisions regarding their
organizations’ formularies, and in the face of … Heparins, low-molecular-weight heparins, and …

… Biosimilar medicines differ from small molecule generic … In the case of endogenous proteins
of human origin, so-called … and the decision-making formulary committee or the physicians, …